Literature DB >> 22508341

Association between glycosylated hemoglobin and intentional weight loss in overweight and obese patients with type 2 diabetes mellitus: a retrospective cohort study.

Ghanshyam Palamaner Subash Shantha1, Anita Ashok Kumar1, Scott Kahan2, Lawrence J Cheskin3.   

Abstract

PURPOSE: The purpose of this study is to assess the relationship between magnitude of weight loss and improvement in percentage A1C (A1C%) among overweight and obese patients with type 2 diabetes mellitus (DM) undergoing weight reduction.
METHODS: Case records of patients enrolled in 2 university-based weight management programs were reviewed. Patients were sampled if they had a diagnosis of DM and had at least 1 documented A1C% reduction from their baseline value. Weight loss treatment was individualized and consisted of a calorie-restricted diet, a behavior modification plan, and a plan for increasing physical activity. Patient weights were measured at bimonthly visits. A1C% was measured every 3 months.
RESULTS: Seventy-two patients formed the study cohort. Mean baseline body mass index was 35.1 kg/m(2), mean age was 52.6 years, and 59% were males. Mean starting A1C% was 8.6. Patients achieved significant mean weight loss (10.7 kg) at study exit. Weight loss of 6.5 kg (4.5% of baseline body weight), 12.2 kg (8.7%), and 15.9 kg (10.3%) was required to reduce A1C% by 0.5, 1, and 1.5, respectively, and it took a mean of 5.6, 8.7, and 10.1 months, respectively, to achieve this. After adjustment for antidiabetic medication intake, for every 10% weight loss, the predicted reduction in A1C% was 0.81.
CONCLUSIONS: Intentional weight loss of 10% can potentially decrease A1C% by 0.81 among patients with type 2 DM. This finding may be clinically useful in encouraging and counseling a patient attempting weight loss.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22508341     DOI: 10.1177/0145721712443293

Source DB:  PubMed          Journal:  Diabetes Educ        ISSN: 0145-7217            Impact factor:   2.140


  12 in total

1.  Effect of individualized diabetes education for type 2 diabetes mellitus: a single-center randomized clinical trial.

Authors:  Min-Hua Fan; Bing-Tong Huang; Ying-Chun Tang; Xiu-Hua Han; Wei-Wei Dong; Le-Xin Wang
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

Review 2.  New and emerging drugs and targets for type 2 diabetes: reviewing the evidence.

Authors:  Brien Rex Miller; Hanh Nguyen; Charles Jia-Haur Hu; Chihyi Lin; Quang T Nguyen
Journal:  Am Health Drug Benefits       Date:  2014-11

3.  Antidiabetic Effects of the Senolytic Agent Dasatinib.

Authors:  Omid Salaami; Chia-Ling Kuo; Matthew T Drake; George A Kuchel; James L Kirkland; Robert J Pignolo
Journal:  Mayo Clin Proc       Date:  2021-11-09       Impact factor: 7.616

4.  Effect of various weight loss interventions on serum NT-proBNP concentration in severe obese subjects without clinical manifest heart failure.

Authors:  Tim Hollstein; Kristina Schlicht; Laura Krause; Stefanie Hagen; Nathalie Rohmann; Dominik M Schulte; Kathrin Türk; Alexia Beckmann; Markus Ahrens; Andre Franke; Stefan Schreiber; Thomas Becker; Jan Beckmann; Matthias Laudes
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

Review 5.  Consequences of obesity and weight loss: a devil's advocate position.

Authors:  R E Brown; J L Kuk
Journal:  Obes Rev       Date:  2014-11-19       Impact factor: 9.213

6.  Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.

Authors:  G E Umpierrez; K M Pantalone; A Y M Kwan; A G Zimmermann; N Zhang; L Fernández Landó
Journal:  Diabetes Obes Metab       Date:  2016-04-13       Impact factor: 6.577

7.  The prevalence and determinants of poor glycemic control among adults with type 2 diabetes mellitus in Saudi Arabia.

Authors:  Riyadh A Alzaheb; Abdullah H Altemani
Journal:  Diabetes Metab Syndr Obes       Date:  2018-01-31       Impact factor: 3.168

8.  Treatment effects on measures of body composition in the TODAY clinical trial.

Authors: 
Journal:  Diabetes Care       Date:  2013-06       Impact factor: 19.112

9.  Triglyceride/HDL ratio as a screening tool for predicting success at reducing anti-diabetic medications following weight loss.

Authors:  Ghanshyam Palamaner Subash Shantha; Anita Ashok Kumar; Scott Kahan; Pavan Kumar Irukulla; Lawrence Jay Cheskin
Journal:  PLoS One       Date:  2013-07-15       Impact factor: 3.240

10.  Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.

Authors:  Hans-Ulrich Häring; Ludwig Merker; Elke Seewaldt-Becker; Marc Weimer; Thomas Meinicke; Hans J Woerle; Uli C Broedl
Journal:  Diabetes Care       Date:  2013-08-20       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.